Compositions and methods for viral sensitization
US-2024360115-A1 · Oct 31, 2024 · US
US9650612B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9650612-B2 |
| Application number | US-201314050710-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 10, 2013 |
| Priority date | Jul 31, 2009 |
| Publication date | May 16, 2017 |
| Grant date | May 16, 2017 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Described herein is a chemostat-like continuous cell culture system that combines certain advantages of perfusion open systems and chemostat open systems to improve the culturing of mammalian cells, e.g., genetically modified cells, particularly in serum-free or chemically-defined media. The continuous culture system described herein involves culturing mammalian cells in a continuous cell culture system, which comprises a cell retention device, wherein the cell culture system has a dilution rate (D) of less than about 2 d −1 , and a cell density of less than about 2×10 7 cell/mL. Also described herein is a method for producing a polypeptide and/or virus of interest in a continuous cell culture, the method comprising culturing mammalian cells expressing the polypeptide and/or virus of interest in a continuous cell culture system, which comprises a cell retention device, wherein the cell culture system has a dilution rate (D) of less than about 2 d −1 , and a cell density of less than about 2×10 7 cell/mL; and recovering the polypeptide and/or virus of interest from medium of the cell culture system.
Opening claim text (preview).
The invention claimed is: 1. A method for producing a virus of interest in a continuous cell culture, said method comprising (a) culturing mammalian cells expressing the virus of interest in a continuous cell culture system, wherein said cell culture system comprises a cell retention device and has a dilution rate (D) of less than 0.8 d −1 and a cell density of less than 2×10 7 cell/mL, wherein the cell retention device produces a cell retention rate of less than 90%; and (b) recovering said virus of interest from medium removed from said cell culture system. 2. The method of claim 1 , wherein said dilution rate is between 0.1 and 0.8 d −1 . 3. The method of claim 1 , wherein said cell density is less than 1×10 7 cell/mL. 4. The method of claim 1 , wherein said cell culture system has a ratio of the dilution rate and a specific growth rate (D/μ) between 1.2 and 5. 5. The method of claim 1 , wherein said cell culture system has a specific growth rate of between 0.2 d −1 and 0.8 d −1 . 6. The method of claim 1 , wherein said cells are cultured in said cell culture system for more than 20 days. 7. The method of claim 1 , wherein said cells are cultured in said cell culture system for more than 40 days. 8. The method of claim 1 , wherein said cells are cultured in said cell culture system for more than 50 days. 9. The method of claim 1 , wherein said dilution rate and said cell density are maintained for at least 80% of the time the cells are cultured in said cell culture system. 10. The method of claim 1 , wherein said cell retention device comprises a macroporous microcarrier. 11. The method of claim 1 , wherein said cells are cultured in a serum-free medium. 12. The method of claim 1 , wherein said cells are cultured in at least 250 L of medium. 13. The method of claim 1 , wherein said cells are non-anchorage dependent cells. 14. The method of claim 1 , further comprising, before the culturing step, pre-culturing the cells in suspension. 15. The method of claim 1 , wherein said cells are genetically modified to express said virus of interest. 16. The method of claim 15 , wherein said cells are CHO cells.
relating to complementing cells and packaging systems for producing virus or viral particles · CPC title
having a known sequence of two or more amino acids, e.g. glutathione · CPC title
Metalloendopeptidases (3.4.24) · CPC title
Xeno-free medium · CPC title
using catalysts, e.g. selective catalysts · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.